Based on the hydrolysis of 2-AG by ABHD12, it was proposed that disruption of the endocannabinoid signaling system was central to the phenotypes observed in PHARC patients and a mouse model [2]. The gene discussed is ABHD12; the disease is PHARC syndrome.